207 related articles for article (PubMed ID: 30967831)
1. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV
Front Neurol; 2019; 10():253. PubMed ID: 30967831
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Coles AJ; Achiron A; Traboulsee A; Singer BA; Pozzilli C; Oreja-Guevara C; Giovannoni G; Comi G; Freedman MS; Ziemssen T; Shiota D; Rawlings AM; Wong AT; Chirieac M; Montalban X
Ther Adv Neurol Disord; 2023; 16():17562864231194823. PubMed ID: 37745914
[TBL] [Abstract][Full Text] [Related]
5. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
Bertolotto A; Arroyo R; Celius EG; Comi G; Havrdova EK; Honeycutt WD; Hunter SF; Izquierdo G; Kornek B; Miller T; Mitsikostas DD; Singer BA; Ziemssen T; Chung L; Daizadeh N; Afsar S; Hashemi L; Senior P
Neurol Ther; 2020 Dec; 9(2):443-457. PubMed ID: 32410147
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
7. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Steingo B; Al Malik Y; Bass AD; Berkovich R; Carraro M; Fernández Ó; Ionete C; Massacesi L; Meuth SG; Mitsikostas DD; Pardo G; Simm RF; Traboulsee A; Choudhry Z; Daizadeh N; Compston DAS;
J Neurol; 2020 Nov; 267(11):3343-3353. PubMed ID: 32583052
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Coles AJ; Arnold DL; Bass AD; Boster AL; Compston DAS; Fernández Ó; Havrdová EK; Nakamura K; Traboulsee A; Ziemssen T; Jacobs A; Margolin DH; Huang X; Daizadeh N; Chirieac MC; Selmaj KW
Ther Adv Neurol Disord; 2021; 14():1756286420982134. PubMed ID: 34035833
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
Okai AF; Amezcua L; Berkovich RR; Chinea AR; Edwards KR; Steingo B; Walker A; Jacobs AK; Daizadeh N; Williams MJ;
Neurol Ther; 2019 Dec; 8(2):367-381. PubMed ID: 31654272
[TBL] [Abstract][Full Text] [Related]
11. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
12. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Arroyo R; Bury DP; Guo JD; Margolin DH; Melanson M; Daizadeh N; Cella D
Mult Scler; 2020 Jul; 26(8):955-963. PubMed ID: 31144568
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.
Ziemssen T; Thomas K
Ther Adv Neurol Disord; 2017 Oct; 10(10):343-359. PubMed ID: 28966663
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.
Havrdova E; Horakova D; Kovarova I
Ther Adv Neurol Disord; 2015 Jan; 8(1):31-45. PubMed ID: 25584072
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
